OC、CIX、CD3AK协同治疗对晚期肿瘤患者免疫功能的影响

发布时间：2018-05-26 14:18

本文选题：DC + CIK　；参考：《新疆医科大学》2015年硕士论文

【摘要】：目的：通过比较晚期恶性肿瘤患者在DC、CIK、CD3AK细胞回输治疗前后外周血CD3+T细胞、CD4+T细胞、CD8+T细胞和CD4+T/CD8+T细胞比值的变化,探讨DC、CIK、CD3AK协同治疗对晚期肿瘤患者免疫功能的影响。方法：收集2014年04月—12月我科行DC、CIK、CD3AK协同治疗的晚期恶性肿瘤患者111例,流式细胞仪检测治疗前后CD3+T细胞、CD4+T细胞、CD8+T细胞的百分比,并计算CD4+ T/CD8+ T细胞比值。结果：①晚期恶性肿瘤患者在回输治疗后CD3+T细胞、CD4+T细胞百分比及CD4+ T/CD8+ T细胞的比值有明显提高,CD8+T细胞百分比降低(P0.05)；②各病种患者回输治疗后CD3+T细胞、CD4+T细胞百分比及CD4+T/CD8+T细胞的比值提高,CD8+T细胞百分比降低(P0.05)；③多疗程组与单疗程组回输治疗后CD3+T细胞、CD4+T细胞百分比及CD4+ T/CD8+ T细胞的比值提高,CD8+T细胞百分比降低,但多疗程组T细胞亚群变化大于单疗程组；④联合放化疗组与未联合组回输治疗后CD3+T细胞、CD4+T细胞百分比及CD4+ T/CD8+ T细胞的比值提高,CD8+T细胞百分比降低细胞百分比降低,但联合治疗组变化大于未联合组。结论：DC、CIK、CD3AK协同治疗能提高晚期肿瘤患者免疫功能；多疗程以及联合放化疗效果更好。
[Abstract]:Objective: to compare the changes of the ratio of CD 4 T cells to CD 8 T cells and CD4 T/CD8 T cells in peripheral CD3 T cells in patients with advanced malignant tumor before and after the patients were treated with DCCIK + CD3AK cells, and to explore the effect of DCCCIK + CD3AK synergistic therapy on the immune function of patients with advanced tumor. Methods: from April to December 2014, 111 patients with advanced malignant tumor treated with DCCCIK CD3AK were collected. The percentage of CD3 T cells, CD4 T cells and CD8 T cells before and after treatment were detected by flow cytometry, and the ratio of CD4 T/CD8 T cells was calculated. Results the percentage of CD3 T cell CD4 T cell and the ratio of CD4 T/CD8 T cell to CD4 T/CD8 T cell were significantly increased in the patients with advanced malignant tumor after retransfusions. The percentage of CD3 T cells in the patients with advanced malignant tumor was significantly decreased after retransfusions. The percentage of CD3 T cells and the ratio of CD4 T/CD8 T cells increased. The percentage of CD3 T cells and the ratio of CD4 T/CD8 T cells increased. However, the changes of T cell subsets in multi-course group were more than those in single-course group. The percentage of CD3 T cell CD4 T cell and the ratio of CD4 T/CD8 T cell to CD4 T/CD8 T cell were decreased after the treatment of combined radiotherapy and chemotherapy, and the ratio of CD4 T/CD8 T cell to CD4 T/CD8 T cell increased. However, the changes in the combined treatment group were greater than those in the uncombined group. Conclusion the immune function of patients with advanced tumor can be improved by the synergistic treatment of CD3AK with the combination of multiple courses of treatment and radiotherapy and chemotherapy.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R730.5

【参考文献】